SCHEMBL30008724

SCHEMBL30008724

Fc1cccc(CNc2ccc(-c3ncnc4[nH]ccc34)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.52
RPS6KB1 P23443 1/20 0.51
TYRO3 Q06418 5/20 0.50
JAK3 P52333 5/20 0.50
DYRK1A Q13627 5/20 0.50
CLK4 Q9HAZ1 5/20 0.50
BTK Q06187 3/20 0.50
AURKA O14965 3/20 0.50
DAPK3 O43293 3/20 0.50
PRKD3 O94806 3/20 0.50
MAP4K4 O95819 3/20 0.50
PAK4 O96013 3/20 0.50
CSF1R P07333 3/20 0.50
RET P07949 3/20 0.50
FGFR1 P11362 3/20 0.50
PRKACA P17612 3/20 0.50
FLT1 P17948 3/20 0.50
LTK P29376 3/20 0.50
GRK5 P34947 3/20 0.50
KDR P35968 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009157 0.85 BTK (0.55) JAK2RPS6KB1TYRO3JAK3DYRK1A
SCHEMBL30008730 0.78 BTK (0.55) JAK2RPS6KB1TYRO3JAK3DYRK1A
SCHEMBL30009296 0.76 KIT (0.60) JAK2JAK3EGFRAURKBIKBKB
SCHEMBL30356051 0.75 JAK1 (0.67) JAK3
SCHEMBL20918022 0.75 JAK1 (0.67) JAK3
SCHEMBL6692696 0.75 FFAR1 (0.67) FFAR1
SCHEMBL30009347 0.74 JAK2 (0.55) JAK2TYRO3JAK3DYRK1ACLK4
SCHEMBL16793627 0.74 JAK2 (0.66) JAK2TYRO3JAK3DYRK1ACLK4
SCHEMBL3119427 0.73 ROCK2 (0.57) JAK3BTKFLT3PDGFRBMELK
SCHEMBL31187292 0.72 JAK2 (0.63) JAK2TYRO3JAK3DYRK1ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 JAK2 61/4885RPS6KB1 532/4885TYRO3 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.